PPARA and Miyoshi myopathy: Moreover, the inhibition of PPAR β/δ by PPAR antagonists resulted in decreased angiogenesis and cell proliferation, suggesting the therapeutic targeting of PPAR, alone or in combination with conventional MM immunotherapies.